|
|
Article: New brain cancer treatment. (Guilford Pharmaceuticals Inc. receives approval to use gliadel wafers to deliver drugs to treat glioblastoma multiforme cancer)(Brief Article)
- Article from:
- FDA Consumer
- Article date:
- December 1, 1996
CopyrightCOPYRIGHT 1996 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
A recently approved implantable wafer is the first technology to deliver an anticancer drug directly to the site of a surgically removed brain tumor in recurrent brain cancer.
Gliadel wafers were approved by FDA on Sept. 24 to treat glioblastoma multiforme, an aggressive type of brain cancer in the malignant glioma class of cancers. Glioblastoma multiforme, which occurs mainly in adults, has been extremely difficult to treat effectively with cancer therapies such as surgery, radiation, and traditional chemotherapy.
Implanted into the cavity of the brain created when a tumor is removed, the wafers--seven or eight of them, depending on the cavity's ...